Akcea Therapeutics (AKCA) Tops Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Akcea Reports Financial Results and Highlights for Third Quarter 2019
November 5, 2019 4:06 PM ESTReported Third Quarter 2019 Global Net Product Revenues of $12 Million
WAYLIVRA® (volanesorsen) launched in the E.U.
Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-LRx
Conference Call Webcast Tuesday, November 5, 4:30 p.m. ET... More
